Calmark presents in the webinar “Strategic Routes for Entering the Chinese Life Science Market”
As a company that has recently entered the Chinese market, Calmark will share its experiences, tips and tricks so far, at the third China webinar hosted by the Swecare Foundation. The webinar will be held on 18 March at 8:30.
The China healthcare industry is ranked the second largest in the world behind the US and is growing at a consistently rapid rate. The third webinar in Swecare's series focusing on the Chinese healthcare market will discuss various options for market entry and offer first-hand insights from two Swedish companies that recently have ventured into the market.
Representatives of Nordic Match, financial advisors to Calmark, will cover various strategies for entering the Chinese life science and healthcare market, such as partnerships, JV, inbound M&A, direct investments and licensing.
Agenda:
08:30 – 08:35 Welcome and Introduction
Anna Riby – Swecare
08:35 – 09:05 What are the different strategic routes to consider when entering China?
Markus Dahlström, Partner, and Tony Wang, Partner, Nordic Match
09:05 - 09:15 Story-sharing from Calmark's China journey
Anna Söderlund, CEO, Calmark
09:15 – 09:25 Story-sharing from Vironova's China journey
Mohammed Homman, CEO, Vironova
09:25 – 09:45 Q&A, discussion and summary
Read more and register here. Participation is free.
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
